Introduction
Serotonin (5-HT) is a cornerstone of modern psychiatry, central to our understanding of emotion regulation and the treatment of mood disorders. However, experimental attempts to link serotonin levels directly to behavior often yield inconsistent results. One common method, Acute Tryptophan Depletion (ATD), which temporarily lowers brain serotonin levels, produces anxiogenic effects in some individuals but not in others. This study investigates whether genetic variations in the Tryptophan hydroxylase 2 (TPH2) gene—the rate-limiting enzyme for serotonin synthesis in the brain—explain this variability. Specifically, researchers examined the rs4570625 polymorphism to determine if certain genotypes are more vulnerable to the effects of transient serotonin fluctuations.
Methodology
The study employed a rigorous within-subject, randomized, double-blind, placebo-controlled pharmacological fMRI design. The sample consisted of 51 healthy male participants, stratified into two groups based on their TPH2 genotype: GG carriers (hypothesized to be more vulnerable) and TT carriers.
Each participant underwent two experimental sessions. In the ATD session, they consumed an amino acid drink lacking tryptophan to induce a temporary drop in serotonin. In the placebo (PLC) session, the drink included tryptophan. Five hours post-ingestion, participants performed an emotional face-matching task during fMRI scanning. This task required them to match facial expressions (angry, fearful, happy, or neutral), allowing researchers to measure neural reactivity to both threat-related and positive stimuli. The primary regions of interest were the ventromedial prefrontal cortex (vmPFC) and the amygdala, components of the brain's "top-down" emotional regulation circuit.
Results
The Necessity of Genetic Stratification
A key finding was that ATD had no significant main effect on subjective mood or neural reactivity when the entire sample was analyzed as a single group. This highlights why previous serotonin research may have been inconsistent: the effects of serotonin depletion are masked unless individual genetic differences are considered.
Subjective Anxiety and the GG Genotype
When accounting for genotype, a clear pattern emerged. GG carriers reported a significant increase in subjective anxious arousal following serotonin depletion compared to the placebo condition ($p = 0.013$). In contrast, TT carriers showed no such increase in anxiety levels under ATD.
Neural Reactivity in the vmPFC
The behavioral findings were mirrored by neural activity in the vmPFC, a region critical for the cognitive regulation of emotion. Under the ATD condition, GG carriers exhibited significantly reduced vmPFC reactivity to threat-related stimuli, specifically fearful ($p = 0.034$) and angry ($p = 0.043$) faces. This suggests that for GG carriers, low serotonin levels impair the prefrontal cortex's ability to process or regulate threat signals.
Furthermore, the researchers found a significant positive correlation ($r = 0.502$) within the GG group: individuals who showed the greatest decrease in vmPFC reactivity also reported the highest levels of subjective anxiety. Interestingly, the study found no robust interaction effects in the amygdala, suggesting that the vulnerability associated with the TPH2 gene is primarily related to prefrontal regulation rather than "bottom-up" emotional reactivity.
Discussion
These results provide evidence that the TPH2 rs4570625 polymorphism determines how an individual's brain and mood respond to a transient decrease in serotonin. The findings suggest that the GG genotype represents a vulnerability factor, where low serotonin leads to a failure in vmPFC-mediated emotion regulation, manifesting as increased anxiety.
While the study is limited by its male-only sample and the relatively small size typical of pharmacological fMRI trials, it has significant implications for personalized medicine. Understanding these genetic predispositions could eventually help clinicians predict which patients might be most sensitive to serotonin-targeting treatments, such as SSRIs, or identify individuals at higher risk for developing anxiety disorders during periods of physiological stress. Future research should aim to replicate these findings in female populations and explore the clinical utility of TPH2 genotyping in psychiatric populations.
Summary updated